Zobrazeno 1 - 10
of 10
pro vyhledávání: '"G Miralles Andreu"'
Autor:
S Gutiérrez Palomo, A Andújar Mateos, MJ Lucas Mayol, C Matoses Chirivella, G Miralles Andreu, A Navarro Ruiz
Publikováno v:
Section 5: Patient safety and quality assurance.
Autor:
O Guillen Martinez, M Pomares Bernabeu, S Gutierrez Palomo, L Soriano Irigaray, G Miralles Andreu, A Navarro Ruiz
Publikováno v:
Section 4: Clinical pharmacy services.
Autor:
I Jiménez Pulido, L Soriano Irigaray, G Miralles Andreu, A Navarro Ruiz, S Gutiérrez Palomo, M Pomares Bernabeu
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance The risk of reactivation due to hepatitis B virus (HBV), including fatal cases, in patients treated with daratumumab was reported in June 2019. Health authorities recommended HBV screening in patients before initiation of da
Autor:
M Pomares-Bernabeu, S Martínez-Pérez, IP Jiménez-Pulido, M Llinares-Esquerdo, A Navarro Ruiz, G Miralles-Andreu
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance According to the EMA product information, in Crohn’s disease (CD), ustekinumab is dosed first by intravenous administration. Patients should then continue with 90 mg ustekinumab subcutaneous every 8 (q8W) or 12 (q12W) week
Autor:
A Navarro Ruiz, S Martínez-Pérez, M Llinares-Esquerdo, S Gutierrez-Palomo, G Miralles-Andreu, A Garcia-Monsalve
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Despite advances in the early detection and treatment of cancer, a large proportion of patients still eventually die as a result of their disease. The quality of medical care delivered to cancer patients near the end of life
Autor:
M Pomares Bernabeu, G Miralles Andreu, A Navarro Ruiz, I Truyols García, L Peral Ballester, L Soriano Irigaray
Publikováno v:
Section 3: Production and Compounding.
Background and importance Mitomycin C is used in different regimens for the treatment of bladder, anus and lung cancer. According to the data sheet, reconstitution of the vial should be carried out with water for preparation of injectables or with 20
Autor:
A Navarro Ruiz, AC Murcia López, L Soriano Irigaray, M Pomares Bernabeu, G Miralles Andreu, M Llinares Esquerdo
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Nivolumab was authorised in Spain in 2015. It is a human immunoglobulin monoclonal antibody that binds to PD-1 receptor and blocks its interaction with PD-L1 and PD-L2. It is indicated in adjuvant or metastatic melanoma (MC)
Autor:
A Navarro Ruiz, L Peral Ballester, C Matoses Chirivella, S Martínez Pérez, G Miralles Andreu, M Pomares Bernabeu
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background Drug shortages can occur for many reasons including manufacturing, quality problems, delays and discontinuations. Nowadays, the number of drug shortages is increasing and finding solutions for them is fundamental. Purpose To analyse drug s
Autor:
M Llinares, AC Murcia López, L Peral Ballester, G Miralles Andreu, A Navarro Ruiz, S Martínez Pérez
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background The adjustment of infliximab (IFX) doses is commonly based on subjective data or invasive methods. However, pharmacokinetic monitoring of IFX plasma levels is a currently available tool that has proved to be useful in the optimisation of c
Autor:
G Miralles Andreu, A Navarro Ruiz, E García Iranzo, M Pomares Bernabeu, I Jiménez Pulido, C Matoses Chirivella
Publikováno v:
Eur J Hosp Pharm
Background During hospital admission, therapeutic interchange (TI) is performed on patients in treatment with angiotensin receptor blockers (ARBs) different from losartan, which are not included in the Pharmacotherapeutic Formulary. After TI, control